The Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）

Randomized phase II study of DTX vs PTX in patients with ESCC refractory to 5-FU- and platinum-based chemotherapy（OGSG1201）

Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer A Phase II Study (OGSG 1107)

Randomized phase II study of CPT‑11 versus PTX versus each combination chemotherapy with S‑1 for advanced gastric cancer that is refractory to S‑1 or S‑1 plus CDDP: OGSG0701

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201

Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108)

切除不能進行・再発大腸癌に対する後方ラインにおける レゴラフェニブ療法とS-1＋ベバシズマブ併用療法の 無作為化比較第Ⅱ相試験（OGSG1301）

A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601)

胃癌術後補助化学療法患者に対する成分栄養剤による栄養サポートの有用性に関する検討 (OGSG1108)

Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）